3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On October 23, 2026, Milestone Pharmaceuticals received a Nasdaq notice that its common shares fell below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 21, 2027 to regain compliance, and Nasdaq says the notice has no present impact on the listing, though failure to comply could lead to delisting.
Nasdaq notice dated October 23, 2026 cites Listing Rule 5450(a)(1) for the $1.00 minimum bid price.
Compliance period runs 180 calendar days, until April 21, 2027, requiring a closing bid of $1.00 or more for at least 10 consecutive business days.
If not compliant, the company may seek a transfer to the Nasdaq Capital Market, which requires a $5,000 application fee, or pursue a reverse stock split.
The filing states there can be no assurance the shares will remain listed.
Eureka Acquisition Corp, a Cayman Islands blank-check style company listed on Nasdaq, received a Nasdaq letter on October 26, 2026 granting it until January 31, 2027 to regain compliance with the public float requirement. The company had not met Nasdaq Listing Rule 5450(a)(4) and submitted a compliance plan on October 12, 2026. The extension means the stock stays listed for now, but the company must still meet the rule by the new deadline.
Nasdaq notice of non-compliance with Public Float Rule (Listing Rule 5450(a)(4)) was received August 27, 2026
Company submitted its compliance plan to Nasdaq on October 12, 2026
On October 26, 2026, Nasdaq granted an extension through January 31, 2027 to regain compliance
Zillow Group entered a settlement agreement on October 27, 2026, to resolve the consolidated securities class action Jaeger v. Zillow Group, Inc. The company will pay $212.5 million in cash into an escrow fund within 20 business days after preliminary court approval, with about $48 million expected to come from insurance proceeds. The settlement is subject to court approval and does not affect the related shareholder derivative actions, which remain pending.
Settlement payment totals $212.5 million, with about $48 million expected from insurance proceeds
Payment due within 20 business days after the court preliminarily approves the settlement
Class covers stock purchases from August 5, 2021, to November 2, 2021; agreement includes no admission of liability
Related shareholder derivative actions remain pending and are not resolved by this settlement
Nasdaq's Hearings Panel granted Rain Enhancement Technologies' request for continued listing, subject to conditions tied to its proposed business combination with Tensor Networks and related financing. The combined company must meet all initial listing criteria by February 16, 2027, so the decision keeps the stock listed for now but depends on meeting those milestones.
Nasdaq Hearings Panel granted continued listing, subject to conditions
Conditions include milestones tied to the proposed Tensor Networks business combination and related financing
Combined company must comply with all initial listing criteria by no later than February 16, 2027
Class A common stock and warrants continue to trade on The Nasdaq Capital Market as RAIN and RAINW
Beneficient and certain subsidiaries filed a motion to intervene in Delaware Court of Chancery litigation brought by HCLP Nominees against Delaware Trust Company, seeking to invalidate HCLP credit agreements and cancel the purported obligations. The company says success would eliminate about $130 million of purported HCLP debt and leave it with an unleveraged balance sheet, but the motion is subject to court approval and no definitive agreement has been reached.
The motion to intervene was filed October 23, 2026, and the company seeks to recover about $211 million it previously paid on the purported debt.
If successful, the action would eliminate about $130 million of purported HCLP debt and establish that HCLP has no valid right to the related collateral.
Former CEO Brad Heppner was convicted of securities fraud and wire fraud in May 2026; his sentencing is rescheduled for January 11, 2027.
No definitive agreement on a consensual resolution with Heppner has been reached, and the filing states that negotiations and litigation do not assure a particular outcome.
Palvella Therapeutics said the FDA accepted for filing and granted Priority Review to its New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations, with a Prescription Drug User Fee Act target action date of February 28, 2027. The company says the drug could be the first FDA-approved therapy for this condition and is preparing for a potential U.S. launch in the first half of 2027, but approval is not assured.
FDA accepted the NDA and granted Priority Review for QTORIN 3.9% rapamycin anhydrous gel
PDUFA target action date set for February 28, 2027
Phase 3 SELVA study met all six prespecified efficacy endpoints (all p<0.001)
Potential standalone U.S. commercial launch planned for the first half of 2027, subject to FDA approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.